Gland Pharma freezes at 20% upper circuit
Gland Pharma freezes at 20% upper circuit on strong June quarter show
The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent
Shares of Gland Pharma were locked in the 20 per cent upper circuit at Rs 1,612.60 on the BSE in Tuesday’s intra-day trade after the company reported improved financial performance for the June quarter (Q1).
The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent.
The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent
Shares of Gland Pharma were locked in the 20 per cent upper circuit at Rs 1,612.60 on the BSE in Tuesday’s intra-day trade after the company reported improved financial performance for the June quarter (Q1).
The firm's gross profit margin was up 700 bp year-on-year (YoY) to 63 per cent for Q1 due to lower raw material costs. On a sequential basis, gross profit margin improved by 900 bp from 54 per cent.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.